Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

September 30, 2018

Conditions
Psychiatric DisordersCognitive ImpairmentChronic Hepatitis c
Interventions
OTHER

Neuropsychiatric screening

"Psychiatric diagnosis through:~1. clinical interview~2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~3. HAM-D (Hamilton Scale for Depression);~4. PHQ-9 (Patient's Health Questionnaire-9 items);~5. MDQ (Mood Disorders Questionnaire);~6. YMRS (Young Mania Rating Scale);~7. ASRM (Altman Self Rating Mania scale);~8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~ Assessment of Quality of Life:~9. SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R)."

Trial Locations (1)

09042

Policlinico Universitario di Monserrato, Monserrato

All Listed Sponsors
lead

Azienda Ospedaliero Universitaria di Cagliari

OTHER

NCT03313154 - Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related | Biotech Hunter | Biotech Hunter